The global induced pluripotent stem cells market size is calculated at USD 2.13 billion in 2025 and is expected to reach ...

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class ...

Extraembryonic trophoblast lineages constitute the placenta, and are essential for individual development. In human early embryo development, these cells can be generated from totipotent blastomeres.

This is especially problematic in cases of blocked blood vessels, which can repeatedly starve large areas of the heart of ...

Organoids were cultured from healthy donor iPSC sources and differentiated using the human iPSC-derived Cerebral Organoid ...

Conventional human pluripotent stem cells at the primed pluripotent state are capable of generating all the embryonic lineages. However, their ...

Racial disparities in mortality are increasing. This article explores how the production of DNA-edited ethnically diverse ...

Kenai Therapeutics, a biotechnology company leveraging induced pluripotent stem cell (iPSC) technology to discover and develop a platform of off-the-s ...

Fate Therapeutics uses iPSC and gene editing to offer scalable off-the-shelf therapies. Read more to see why I rate FATE ...

Scientists from the German Cancer Research Center (DKFZ) and ShanghaiTech University have developed an innovative method for ...

Researchers have developed engineered heart muscle allografts from stem cells, showing promising results in repairing heart damage in primates and humans.